PresentationI'm pleased to introduce the CEO of the company; Robert Wessman, the CFO of the company; Linda Jonsdottir, the CEO; Joseph McClellan, and the Head of Investor Relations, which is Patrik Ling. There is one page in the presentation with the convertible bond terms. We can go through that afterwards. There will also be a Q&A session [Operator Instructions].Robert WessmanCEO, Founder & Executive Chairman Yes. Thank you so much. First of all, I want to thank you, everyone, for joining in here today, a ...

Year-end trading on Wall Street follows a familiar pattern, and the same question resurfaces once again: will the Santa Claus rally make an appearance?The stretch between Christmas and the first trading days of January is historically known for the Santa Claus rally, a period when stocks have typically pushed higher amid lighter volumes, tax-driven trades and year-end optimism.It's a pattern that's been debated, dismissed, and rediscovered for decades, yet the numbers keep pulling investors back in.S&P 500' ...

PresentationI will now hand the conference over to Vivian Wu, Investor Relations and Corporate Affairs. Vivian, please go ahead.Ladies and gentlemen, thank you for joining us, and welcome to Nektar Therapeutics' Analyst and Investor event to discuss RESOLVE-AA top line results. [Operator Instructions]Vivian WuInvestor Relations Thank you, and good morning, everyone. Thank you for joining us today. Today, you will hear from Howard Robin, our President and Chief Executive Officer; Dr. Jonathan Zalevsky, our ...

Shares of Cellectis S.A. (NASDAQ:CLLS) tanked on Tuesday after Allogene Therapeutics Inc. (NASDAQ:ALLO) cited a favorable arbitration outcome for partner Servier in its dispute with Cellectis related to the CAR-T therapy cemacabtagene ansegedleucel (cema-cel).The win reconfirmed Allogene’s full development and commercial control of cema-cel in the U.S., the EU and the U.K., while clearing the path to obtain full global commercialization rights from Servier.Also Read: Why Cellectis Stock Is Trading Higher To ...

Newborn screening is the only practical means of diagnosing MLD prior to the onset of symptoms, which is key to achieving optimal outcomes for children and their families with this rapidly progressive disease As of today, 14 states—representing more than 50 percent of U.S. births—have RUSP-aligned legislation intended to expedite the addition of newly approved RUSP conditions to their respective NBS panels Other community-led efforts to enable newborn screening for MLD advancing globally TOKYO, LONDON and B ...

December 16, 2025 1 Forward-Looking Statements Neurocrine Biosciences R&D Day 2025 In addition to historical facts, this presentation contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to: our business strategy, objectives, and future development plans; the benefits to be derived from our products and product candidates; the value our products and/or our product candidates may bring to patients; the conti ...

MILWAUKEE, Dec. 16, 2025 /PRNewswire/ -- The Ademi Firm continues to investigate Mersana (NASDAQ: MRSN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Day One Biopharmaceuticals. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you. In the tender offer transaction, Mersana shareholders will receive $25.00 per shar ...

Nektar Therapeutics (NASDAQ:NKTR) on Tuesday revealed topline results from the 36-week induction treatment period of the Phase 2b REZOLVE-AA trial of investigational rezpegaldesleukin.The global Phase 2b study is being conducted in 92 patients with severe-to-very-severe alopecia areata.Alopecia areata is an autoimmune condition where the immune system attacks hair follicles, causing sudden, patchy hair loss, usually in coin-sized spots, but it can progress to total scalp (alopecia totalis) or body (alopecia ...

“Imagine if you work as hard as you can, would the world become a bit better or worse? I believe with Iso it's definitely better.” That’s Software Engineer @aberezhk from our Lausanne office sharing why @IsomorphicLabs’ mission to solve all disease inspires her work.Read more from Anna and the Lausanne team on our blog, and check out our open roles. You can find the link in the comments below. ...

Oppenheimer raised the firm’s price target on Palvella Therapeutics (PVLA) to $200 from $120 and keeps an Outperform rating on the shares after the company reported the Phase 2 TOIVA readout for Qtorin rapamycin in cutaneous venous malformations. The firm says 10 of 15 patients presented as “much improved” or “very much improved” over just 12 weeks. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, shar ...